GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pangen Biotech Inc (XKRX:222110) » Definitions » Debt-to-Equity

Pangen Biotech (XKRX:222110) Debt-to-Equity : 0.13 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Pangen Biotech Debt-to-Equity?

Pangen Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩2,100 Mil. Pangen Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩2 Mil. Pangen Biotech's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩16,630 Mil. Pangen Biotech's debt to equity for the quarter that ended in Mar. 2024 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pangen Biotech's Debt-to-Equity or its related term are showing as below:

XKRX:222110' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03   Med: 0.6   Max: 1.52
Current: 0.13

During the past 10 years, the highest Debt-to-Equity Ratio of Pangen Biotech was 1.52. The lowest was 0.03. And the median was 0.60.

XKRX:222110's Debt-to-Equity is ranked better than
52.89% of 1072 companies
in the Biotechnology industry
Industry Median: 0.14 vs XKRX:222110: 0.13

Pangen Biotech Debt-to-Equity Historical Data

The historical data trend for Pangen Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pangen Biotech Debt-to-Equity Chart

Pangen Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.94 1.30 0.89 - 0.16

Pangen Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.10 0.12 0.16 0.13

Competitive Comparison of Pangen Biotech's Debt-to-Equity

For the Biotechnology subindustry, Pangen Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pangen Biotech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pangen Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pangen Biotech's Debt-to-Equity falls into.



Pangen Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pangen Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Pangen Biotech's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pangen Biotech  (XKRX:222110) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Pangen Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pangen Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Pangen Biotech (XKRX:222110) Business Description

Traded in Other Exchanges
N/A
Address
4Floor Innoplex 2-dong, 306 Sinwon-ro, Yeongtong-gu, Gyeonggi-do, Suwon-si, KOR, 16675
Pangen Biotech Inc is a biotechnology company. It is engaged in development of biosimilar products and technology transfer services for biologics development. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc.

Pangen Biotech (XKRX:222110) Headlines

No Headlines